Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Lack of relationship between quinidine pharmacokinetics and the sparteine oxidation polymorphism

  • 37 Accesses

  • 9 Citations


Quinidine is a very potent inhibitor of CYP2D6, but the role of the enzyme in the biotransformation of quinidine has only been investigated in a single in vitro study and in two small in vivo experiments, with contradictory results. The present investigation was designed to present definite evaluation of whether quinidine is metabolised by CYP2D6. Eight poor metabolizers (PM) and 8 extensive metabolizers (EM) of sparteine each took one oral dose of 200 mg quinidine. In the EM, the total clearance, the clearance via 3-hydroxylation and the clearance via N-oxidation, were 33, 3.7 and 0.23 l·h−1, respectively. In the PM, the corresponding values were 29, 3.1 and 0.18 l·h−1, respectively. There were no statistically significant differences between EM and PM in any of these pharmacokinetic parameters. It is concluded that CYP2D6 is not an important enzyme for the oxidation of quinidine.

This is a preview of subscription content, log in to check access.


  1. 1.

    Otton SV, Inaba T, Kalow W (1984) Competitive inhibition of sparteine oxidation in human liver by beta-adrenoreceptor antagonists and other cardiovascular agents. Life Sci 34:73–80

  2. 2.

    Inaba T, Nakano M, Otton SV, Mahon WA, Kalow W (1985) A human cytochrome P450 characterized by inhibition studies of the sparteine-debrisoquine monooxygenase. Canad J Physiol Pharmacol 62:860–862

  3. 3.

    Brinn R, Brøsen K, Gram LF, Haghfelt T, Otton SV (1986) Sparteine oxidation is practically abolished in quinidine-treated patients. Br J Clin Pharmacol 22:194–197

  4. 4.

    Brøsen K, Gram LF, Haghfelt T, Bertilsson L (1987) Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment. Pharmacol Toxicol 60:312–314

  5. 5.

    Otton SV, Brinn RU, Gram LF (1988) In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver. Drug Metab Dispos 16:15–17

  6. 6.

    Mikus G, Ha HR, Vozeh S, Zekorn C, Follath F, Eichelbaum M (1986) Pharmacokinetics and metabolism of quinidine in extensive and poor metabolizers of sparteine. Eur J Clin Pharmacol 31:69–72

  7. 7.

    Brøsen K, Davidsen F, Gram LF (1990) Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man. Br J Clin Pharmacol 29:248–253

  8. 8.

    Smith E, Barhan S, Ross B, Maienthal M, Levine J (1973) Examination of quinidine and quinine and their pharmaceutical preparations. J Pharm Sci 62:1151–1155

  9. 9.

    Brøsen K, Otton SV, Gram LF (1985) Sparteine oxidation polymorphism in Denmark. Acta Pharmacol Toxicol 57:357–360

  10. 10.

    Nielsen F, Nielsen KK, Brøsen K (1994) Determination of quinidine, dihydroquinidine, (3S)-3OH-quinidine and quinidine-N-oxide in plasma and urine, by high-performance liquid chromatography. J Chromatogr 660:103–110

  11. 11.

    Drayer DE, Lowenthal DT, Restivo K, Schwartz KM, Cook CE, Reidenberg MM (1978) Steady state serum levels of quinidine and active quinidine metabolites in cardiac patients with varying degrees of renal function. Clin Pharmacol Ther 24:31–39

  12. 12.

    Leroyer R, Varoquaux O, Advenier C, Pays M (1990) Quinidine oxidative metabolism. Identification and biosynthesis of quinidine-10, 11-dihydrdiol stereoisomers. Biomed Chromatogr 4:61–64

  13. 13.

    Wolff T, Distlerath LM, Worthington MT, Groopman JD, Hammons GJ, Kaludbar FF, Prough RA, Martin MV, Guengerich FP (1985) Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modelling. Cancer Res 45:2116–2122

  14. 14.

    Meyer UA, Gut J, Kronbach T, Skoda C, Meier UT, Catin T (1986) The molecular mechanisms of two common polymorphisms of drug oxidation — evidence for functional changes in cytochrome P-450 isozymes catalyzing bufaralol and mephenytoin oxidation. Xenobiotica 16:449–464

  15. 15.

    Koymans L, Vermeulen NPE, vanAcker ABE, teKoppele JM, Keykants JP, Lavrijsen K, Meuldermans W, Donné-Op den Kelder GM (1992) A predictive Model for Substrates of Cytochrome P450-Debrisoquine (2D6). Chem Res Toxicol 5: 211–219

  16. 16.

    Dohorty R, Benson WR, Maienthal M, Stewart JMcD (1978) Crystal and Molecular Structure of Quinidine. J Pharm Sci 67:1698–1701

  17. 17.

    Guengerich FP, Müller-Enoch D, Blair IA (1986) Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol: 287–290

  18. 18.

    Spinler SA, Cheng JWM, Kindwall KE, Charland SL (1995) Possible inhibition of hepatic metabolism of quinidine by erythromycin. Clin Pharmacol Ther 57:89–94

Download references

Author information

Correspondence to F. Nielsen.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Nielsen, F., Rosholm, J.U. & Brøsen, K. Lack of relationship between quinidine pharmacokinetics and the sparteine oxidation polymorphism. Eur J Clin Pharmacol 48, 501–504 (1995).

Download citation

Key words

  • Quinidine
  • CYP2D6
  • Sparteine oxidation polymorphism
  • (3S)-3OH-quinidine
  • quinidine-N-oxide
  • dihydroquinidine
  • pharmacokinetics